Grifols Overview

  • Founded
  • 1909

Founded
  • Status
  • Public

  • Employees
  • 27,000

Employees
  • Stock Symbol
  • GRF

Stock Symbol
  • Investments
  • 40

  • Share Price
  • $11.00

  • (As of Thursday Closing)

Grifols General Information

Description

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue (following the Biotest acquisition).

Contact Information

Website
www.grifols.com
Formerly Known As
Probitas Pharma
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Other Pharmaceuticals and Biotechnology
Stock Exchange
MAD
Primary Office
  • Avinguda de la Generalitat, 152
  • Parc empresarial Can Sant Joan, Sant Cugat del Vallès
  • 08174 Barcelona
  • Spain
+34 935 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Grifols Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.00 $10.48 $7.65 - $21.76 $6.44B 679M 1.68M $0.11

Grifols Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 20,526,189 21,671,864 26,531,860 28,721,160
Revenue 5,863,330 5,832,419 6,087,178 5,707,703
EBITDA 1,014,204 1,102,472 1,613,047 1,488,573
Net Income 73,830 223,130 705,089 699,816
Total Assets 21,977,284 21,776,947 18,787,469 17,410,399
Total Debt 9,982,434 10,557,173 8,500,792 7,960,938
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Grifols Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Grifols‘s full profile, request access.

Request a free trial

Grifols Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sel
Biotechnology
Barcelona, Spain
27,000 As of 2022
000000000

000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000000000 000000000
Kobe, Japan
0000 As of 0000
00000000

000-00

met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000000000 000000000
Hercules, CA
0000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Grifols Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sysmex Corporation Corporation Kobe, Japan 0000 00000000
000-000 0000000000 Corporation Hercules, CA 0000 00000 00000000 00000
000 Corporation Parkville, Australia 00000 00.000 000000000 00.000
0000 0000000000000 Corporate Backed or Acquired Petah Tikva, Israel 00000 00000 00000000000 00000
00000 Corporation Osaka, Japan 00000 00000000
You’re viewing 5 of 9 competitors. Get the full list »

Grifols Patents

Grifols Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4062926-A1 Use of albumin for the treatment of defective b-cell function Pending 25-Mar-2021 000000000 0
EP-4052723-A1 Alpha-1 antitrypsin dosing regimen Pending 02-Mar-2021 000000000 0
EP-4032661-A1 Machine for the preparation of pharmaceutical products Pending 22-Jan-2021 00000000 0
EP-3984455-A1 Unit for collecting blood and/or plasma Pending 15-Oct-2020 000000000 0
EP-3915574-A1 Method for the treatment of cytokine release syndrome Inactive 27-May-2020 A61K38/57
To view Grifols’s complete patent history, request access »

Grifols Executive Team (38)

Name Title Board Seat Contact Info
Raimon Roura Co-Chief Executive Officer & Board Member
Víctor Deu Co-Chief Executive Officer & Board Member
Alberto Roura Board Member
Antoni Fages President
Joel Abelson President, Bioscience Commercial Division
You’re viewing 5 of 38 executive team members. Get the full list »

Grifols Board Members (17)

Name Representing Role Since
00000 0000000 00.0 Grifols Independent Director, Audit Committee member 000 0000
000000 000000 Self Board Member 000 0000
000000000 0000 00. Grifols Board Member 000 0000
00000 00000000 Grifols Board Member 000 0000
00000 000000 Grifols Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Grifols Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Grifols Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Grifols‘s full profile, request access.

Request a free trial

Grifols Investments & Acquisitions (40)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 15-Jun-2022 0000000000 00000 Biotechnology
0000000 25-Apr-2022 0000000000 00.000 Drug Discovery 000000 00
0000000 00000 07-Apr-2021 000000000 000.00 Buildings and Property
0000000 09-Mar-2021 0000000000 0000 Drug Discovery 0í0000 00
BPL Plasma (25 US-based plasma centres) 28-Feb-2021 Corporate Asset Purchase 00000 Buildings and Property
You’re viewing 5 of 40 investments and acquisitions. Get the full list »

Grifols Subsidiaries (9)

Company Name Industry Location Founded
Alkahest Drug Discovery San Carlos, CA 2014
0000 00000000 Diagnostic Equipment Arrasate, Spain 0000
0000000 Drug Discovery San Francisco, CA 0000
000000 00000000000 Biotechnology Vista, CA 0000
0000000 0000000 Biotechnology Zaragoza, Spain 0000
You’re viewing 5 of 9 subsidiaries. Get the full list »

Grifols Exits (7)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 09-Nov-2020 000000000 00000000 000.00 Completed
  • 0000000
0000000 000000 01-Aug-2018 000000000000000000 00000 Completed
  • 0000000
00000 04-Jun-2018 000000000000000000 00000 Completed
  • 0000000
000000000 26-Jan-2018 000000000000000000 0000 Completed
  • 0000000
Singulex 17-May-2016 Later Stage VC 000.00 Completed
You’re viewing 5 of 7 exits. Get the full list »